



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

Exploring the binding mechanism of the main proteinase in SARS-associated coronavirus and its implication to anti-SARS drug design

Xue Wu Zhang* and Yee Leng Yap

HKU-Pasteur Research Center, Bioinformatics, 8 Sassoon Road, Hong Kong, China

Received 24 November 2003; revised 10 February 2004; accepted 10 February 2004

Abstract—The main proteinase of SARS-associated coronavirus (SARS-CoV) plays an important role in viral transcription and replication, and is an attractive target for anti-SARS drug development. The important thing is to understand its binding mechanism with possible ligands. In this study, we investigated possible noncanonical interactions, potential inhibitors, and binding pockets in the main proteinase of SARS-CoV based on its recently determined crystal structure. These findings provide a wide clue to searching for anti-SARS drug. Interestingly, we found that similar structure patterns exist in SARS-CoV main proteinase with Poliovirus 3c Proteinase, Rhinovirus 3c Protease, Nsp4 Proteinase From Equine Arteritis Virus, Hepatitis C Virus Ns3 Protease, Hepatitis A Virus 3c Protease, and Dengue Virus Ns3 Protease. It suggests that the available drugs in these viruses could be used to fight SARS disease.

© 2004 Elsevier Ltd. All rights reserved.

1. Introduction

Since November in 2002, a highly contagious pneumonia, severe acute respiratory syndrome (SARS), has spread rapidly in Asia, North America, and Europe. A new SARS coronavirus (SARS-CoV) has been identified as the etiological agent of the disease. Its seriousness lies in rapid transmission and high fatality (around 15%). However, the origin of SARS-CoV is still unknown, and no effective drug or vaccine is available up to now.

The SARS-CoV replicase encodes two overlapping polyproteins, pp1a and pp1b, which mediate viral replication and transcription. While a special main proteinase, 3C-like proteinase, is responsible for the cleavage of polyproteins, its functional importance make it an attractive target for drug development. Fortunately, the crystal structures of SARS-CoV main proteinase has been determined,^{1,2} which adopt a serine-

protease fold and is homologous to the main proteinases from human coronavirus and transmissible gastroenteritis virus.³ The goal of this study is to find potential inhibitors and locate the ligand-binding sites in SARS-CoV main proteinase based on comparison of nonhomologous tertiary structures, hence to provide clues to rational drug design.

2. Materials and methods

The atomic coordinates of SARS-CoV main proteinase were downloaded from Protein Data Bank (ID 1Q2W). NCI program⁴ was used to identify noncanonical interactions. VAST (<http://www.ncbi.nlm.nih.gov/Structure/VAST/vastsearch.html>) and DALI (<http://www.ebi.ac.uk/dali/>) programs were used to find similar structure patterns and in the main proteinase structure of SARS-CoV. The structure alignment was done by CE⁵ and the structural comparison was performed by LGA.⁶ The constituents of the binding pocket are determined by those residues that have at least one heavy atom (other than hydrogen) with a distance less than 5 Å from a heavy atom of inhibitor, as did in Chou et al.⁷ The visualization of 3D structure was generated

Keywords: SARS-CoV; Main proteinase; Noncanonical interactions; Inhibitor; Binding.

* Corresponding author. Tel.: +852-2816-8407; fax: +852-2872-5782; e-mail: xwzhang@hkucc.hku.hk

by PROTEINEXPLORER (<http://www.proteinexplorer.org>).

3. Results and discussion

The noncanonical interactions in SARS-CoV main proteinase structures are shown in Figure 1. There are two pairs of main chain-side chain interactions: Glu288 (donor) and Trp 207 (acceptor), Ile152 (donor) and Phe8 (acceptor). There are four pairs of side chain-side chain interactions: Arg40 (donor) and Tyr54 (acceptor), Arg298 (donor) and Phe8 (acceptor), Pro184 (donor)

and Phe185 (acceptor), and Tyr126 (donor) and Phe140 (acceptor). These residues are marked as '@' in Figure 2.

Among these interactions, Phe8 accepts two N–H... π bonds in a sandwich fashion, one donated by a side-side chain Arg298, and one donated by a main-side chain Ile152, as existed in human rac1.⁸ Taken together with another N–H... π interaction between Glu288 and Trp207, these noncanonical bindings connected N-terminus and C-terminus of the enzyme together, then fixed to Ile152 (domain II) and Trp207 (domain III), this makes the domain II and III not flexible due to the loop formed by above interactions in the right and a loop already existed in the left (Fig. 1A), that is stabilizes the structure of the protease. Furthermore, we turn to examine the remaining three pairs of interactions: Arg40 and Tyr54, Pro184 and Phe185, and Tyr126 and Phe140. It can be seen from Figure 1B that these noncanonical bindings will be able to stabilize the protein structure around the active center formed by Cys-His catalytic dyad (Cys145 and His41). On the other hand, after binding, the small helix Arg40 and His41 locate will expect to move up, the loop Phe140 and Cys145 locate and the loop Pro184 and Phe185 locate will expect to move down, hence make the active center more open for substrate binding (Fig. 1B). These results can be used for rational design of mutagenesis experiments and analysis of conservation of interactions at functional sites. In recent years, the noncanonical interactions have been shown to be important for the stability of protein structure^{9–11} and ligand recognition.¹²

The structurally similar nonhomologous virus proteins identified by VAST and DALI methods focus on 6 proteases: 1CQQ (Rhinovirus 3c Protease With Ag7088 Inhibitor), 1L1N (Poliovirus 3c Proteinase), 1MBM (Nsp4 Proteinase From Equine Arteritis Virus), 1DY8 (Hepatitis C Virus Ns3 Protease with inhibitor FKI), 1QA7 (Hepatitis A Virus 3c Protease with inhibitor NFA) and 1DF9 (Dengue Virus Ns3-Protease Complexed With Mung-Bean Bowman–Birk Inhibitor). The structure-based sequence alignment of the above six proteases with SARS-CoV main protease is shown in Figure 2. The results demonstrate that a number of similar beta sheets (marked by b) exist. In particular, there are three similar structural patterns showing conservative residues (bold representation). The catalytical important residues are included in the first two highly conservative patterns: His-Cys or His-Ser catalytic dyads.^{2,13–18} In the third pattern, Gly is conservative in 6 proteases except SARS-CoV main proteinase, the significance of mutation from Gly161 to Tyr161 in SARS is unclear. Anyway, the three structural patterns form the common active center of these seven enzymes, as seen in their superpositions (Fig. 3).

Since these nonhomologous virus proteases share the same active center, we can consider the possibility of applying the inhibitors from these enzymes to SARS-CoV main proteinase. In fact, Anand et al.³ has indicated that the inhibitor AG7088 may be modified to make it useful for SARS therapy. Chou et al.⁷




Figure 1. Noncanonical interactions in the structure of SARS-CoV main proteinase. (A) The residue pairs involved are: Arg298 and Phe 8, Glu288 and Trp207, and Ile152 and Phe8, which are colored blue. (B) The residue pairs involved include: Arg40 and Tyr54, Pro184 and Phe185, and Tyr126 and Phe140, which are colored blue. The Cys-His catalytic dyad (Cys145 and His41) are colored green.

		@		#		@#		###	@
1Q2W:A	0	AFPSGKVEGCMVQVTCG----	TTTLNGLWLD---	DTVYCPRHVIC---	TAEDMLNPNYEDLLIRKSNH				
1L1N:A	0	DYAVAMAKRNIVTATTS----	KGEFTMLGVH---	DNVAILP [#] HASP-----	-----	GE			
1CQQ:A	0	-FGMSLIKHNSCVITTE-----	NGKFTGLGVY---	DRFVVVPT [#] HAD-----	-----	PG			
1MBM:B	0	-----NVGFVAG-----	SSYGTGSVWTRNNEVVLTASH [#] VVGRAN-	-----	-----	MA			
1DY8:A	0	-----DGEVQVLSTA-----	TQSFLATCVN---	G-VCWTVY [#] HGAG-----	-----	SK			
1QA7:A	0	LEIAGLVRKNLVQFGVGEKNGSVR [#] WMNALGVK-	DDWLLVPSHAYK [#] FEKDYE-----	-----	-----	MME			
1DF9:A	0	-----RIKQKGILGY-----	SQIGAGVYKE---	G-TFHTM [#] HVT-----	-----	RGA			
		bbbbbb	bbbbbb	bbbb					
1Q2W:A	70	SFLVQAGNVQL---RVIGHSMQ-----	NCLLRLKV---	DTSNPKTPK--	YKFVRI---	QPQGTFSVL			
1L1N:A	70	SIVID--GKEV---EILDAKALEDQAGT [#] NLEITITL---	KRNEKFRDIRPHIPTQI---	-----	-----	TETNDGVLI			
1CQQ:A	70	KEIQV-DGITT---KVIDSYDLYNKNGIKLEITVLK [#] L---	DRNEKFRDIRRYIPNNE---	-----	-----	DDYPNCNLA			
1MBM:B	70	TLKIG--DAML---TL-TFKKN-----	GDFAEAVTTQSELPGNWPQLH--	FA--Q--	-----	PTTGPASWC			
1DY8:A	70	TL-----AGPKGPITQMYTNV-----	DQDLVGWPA-----	PPGARSMT-	PCTCG--	SSD--LYLV			
1QA7:A	70	FYFNRGGTYYS-ISAGNVVIQSLDV---	GAQDVVLMKV--	PTIPKFRDITQHFIKKGDVPRALNRLATLV					
1DF9:A	70	VLMHK---GKR---IEPSWADV-----	KKDLVSC-----	GGGWKLE-	GEWKE--	GEE--VQVL			
		bb	bbb	bbb	bbbb	bbbb			
		##	#	@		@	###		
1Q2W:A	140	ACYN-GSPSGVYQCAMRPN-----	-----	HTIK-----	-----	GSFLNGSCGSVGFN			
1L1N:A	140	VNTSKYPNMYVPGAVTEQGYLNL-----	GGRTARTLMYN-----	-----	-----	FPTRAGQCGGVITC			
1CQQ:A	140	LLANQPEPTIINVGDVVSYGNILL-----	SGNQ [#] TARMLKYS-----	-----	-----	YPTKSGYCGGVLYK			
1MBM:B	140	TAT---GDEEGLLSGE-----	-----	VCL-----	-----	AWTTS [#] GS [#] SAVVQ			
1DY8:A	140	TR---HADVIPVRRRG-----	-----	DSRGS [#] L-----	-----	LSRPVSYLK [#] SG [#] GPLLC			
1QA7:A	140	TTVNG-TPMLISEGPLKMEEKATYVHKNDGTTVDLTV [#] DQAWRGK-----	-----	-----	-----	GEGLP [#] MG [#] GALVS			
1DF9:A	140	AL-----EPGKN-PRAVQ-----	-----	TKPGLFKTNAGTIGAVSLDFSP [#] TSG [#] SPTID					
		b	bbbbbb		b	bbbb			
		@	##	#					
1Q2W:A	210	IDYDCV-SFCY [#] MH [#] MEL---PTGVHAGTDL-----							
1L1N:A	210	TG---KVI [#] GM [#] HVGGN---GSHGFAAALKRSYFT							
1CQQ:A	210	IG---QVL [#] GI [#] HVGGN---GRDGFSAMLLRSYFT							
1MBM:B	210	GD---AVV [#] GV [#] H [#] TGSN---TSGVAYVTT-----							
1DY8:A	210	PS---GHVV [#] GI [#] FRAAVCTRGVAKAVDFIPVESM--							
1QA7:A	210	SNQSIQNAIL [#] GI [#] HVAGG---NSILVAKLVTOEMFQ							
1DF9:A	210	KKG---KVV [#] GI [#] YGNV [#] VTRSGAYVSAIAQTEKSI-							
		bbbbbbbbb	bbbb						

Figure 2. Structure alignment between SARS-CoV main proteinase (1Q2W) and other proteases: 1L1N (Poliovirus 3c Proteinase), 1CQQ (Rhinovirus 3c Protease), 1MBM (Nsp4 Proteinase From Equine Arteritis Virus), 1DY8 (Hepatitis C Virus Ns3 Protease), 1QA7 (Hepatitis A Virus 3c Protease), and 1DF9 (Dengue Virus Ns3-Protease). The residues marked as 'b' indicate similar beta-sheets. The bold residues indicate structurally similar patterns. The residues marked as '@' make noncanonical interactions. The residues marked as '#' make contact with inhibitors.



Figure 3. The superposition of SARS-CoV main proteinase (1Q2W, white) with other proteases: 1L1N (Poliovirus 3c Proteinase, red), 1CQQ (Rhinovirus 3c Protease, orange), 1MBM (Nsp4 Proteinase From Equine Arteritis Virus, yellow), 1DY8 (Hepatitis C Virus Ns3 Protease, blue), 1QA7 (Hepatitis A Virus 3c Protease, gray), and 1DF9 (Dengue Virus Ns3-Protease, green).

conducted the docking studies of KZ7088 (a derivative of AG7088) to the SARS-CoV main proteinase (based on a theoretical model). Here, we studied the possibility of other inhibitors in anti-SARS drug development. Figure 4 shows the structures of docking other inhibitors from HAV, HCV and Dengue virus to SARS-CoV main proteinase, the residues that make contact with these inhibitors are marked as '#' in Figure 2. Furthermore, the corresponding binding pockets are shown in Table 1. The results reveal that these inhibitors can bind to SARS-CoV main proteinase well.

Thus, the results above suggest that there is a link of SARS-CoV to human rhinovirus, Poliovirus, Arteritis virus, HAV, HCV, and Dengue virus. The inhibitors from these viruses could be modified to make them useful for SARS therapy. In fact, Cinatl et al.¹⁹ reported that human interferons, a medicine widely used in HCV patients, was useful for the treatment of SARS. Anyway, whether relationships between SARS-CoV and these pathogens exist or not, the present results provide a wide clue to search for anti-SARS inhibitors.




Figure 4. The interactions between SARS-CoV main protease (1Q2W, white cartoon) with different inhibitors, binding pockets are represented by blue ball-stick. (A) FKI inhibitor from Hepatitis C Virus Ns3 Protease (yellow spacefill). (B) NFA inhibitor from Hepatitis A Virus 3c Protease (yellow spacefill). (C) Bowman-Birk inhibitor from Dengue Virus Ns3-Protease (yellow stick).

Table 1. Binding pockets of SARS-CoV main proteinase for different inhibitors

FKI inhibitor from HCV	NFA inhibitor from HAV	Bowman-Birk inhibitor from Dengue virus		
VAL	20 MET	17 GLN	19 PHE	140
THR	25 VAL	18 VAL	20 LEU	141
THR	26 GLN	19 THR	21 ASN	142
LEU	27 VAL	20 CYS	22 GLY	143
ASN	28 THR	21 GLY	23 SER	144
PRO	39 THR	24 THR	24 CYS	145
ARG	40 THR	25 THR	25 GLY	146
HIS	41 THR	26 HR	26 SER	147
VAL	42 LEU	27 LEU	27 TYR	161
CYS	44 ASN	28 ASN	28 MET	162
CYS	117 GLY	29 PRO	39 HIS	163
TYR	118 HIS	41 ARG	40 HIS	164
ASN	119 VAL	42 HIS	41 MET	165
SER	139 GLN	69 VAL	42 GLU	166
PHE	140 ALA	116 ILE	43 LEU	167
LEU	141 CYS	117 CYS	44 PRO	168
ASN	142 TYR	118 MET	49 THR	169
GLY	143 ASN	119 LEU	50 GLY	170
SER	144 GLY	120 ASN	51 VAL	171
CYS	145 SER	121 PRO	52 HIS	172
GLY	146 PRO	122 ASN	53 ALA	173
SER	147 LEU	141 TYR	54 GLY	174
TYR	161 ASN	142 LEU	57 PHE	181
HIS	163 GLY	143 VAL	114 PRO	184
HIS	164 SER	144 CYS	117 PHE	185
MET	165 CYS	145 TYR	118 VAL	186
GLU	166 GLY	146 ASN	119 ASP	187
LEU	167 SER	147 TYR	126 ARG	188
VAL	171	THR	135 GLN	189
HIS	172	ILE	136 THR	190
ALA	173	LYS	137 ALA	191
PHE	181	GLY	138 GLN	192
ASP	187	SER	139 ALA	193
			ALA	194

References and notes

- Bonanno, J. B.; Fowler, R.; Gupta, S.; hendle, J.; Lorimer, D.; Romero, R.; Sauder, M.; Wei, C. L.; Liu, E. T.; Burley, S. K.; Harris, T. X-ray crystal structure of the SARS coronavirus main protease. (in press) (<http://www.rcsb.org/pdb/cgi/explore.cgi?pdbId=1Q2W>).
- Yang, H.; Yang, M.; Ding, Y.; Liu, Y.; Lou, Z.; Zhou, Z.; Sun, L.; Mo, L.; ye, S.; Pang, H.; Gao, G.; Anand, K.; Bartlam, M.; Hilgenfeld, R.; Rao, Z. The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor. *Proc. Natl. Acad. Sci. U.S.A.* **2003**, *100*, 13190–13195.
- Anand, K.; Ziebuhr, J.; Wadhwani, P.; Mesters, J. R.; Hilgenfeld, R. Coronavirus main proteinase (3CL^{pro}) structure: basis for design of anti-SARS drugs. *Science* **2003**, *300*, 1763–1767.
- Babu, M. M. NCI: a server to identify non-canonical interactions in protein structures. *Nucleic Acids Res.* **2003**, *31*, 3345–3348.
- Shindyalov, I. N.; Bourne, P. E. Protein structure alignment by incremental combinatorial extension (CE) of the optimal path. *Protein Eng.* **1998**, *11*, 739–747.
- Zemla, A. LGA: a method for finding 3D similarities in protein structures. *Nucleic Acids Res.* **2003**, *31*, 3370–3374.
- Chou, K.; Wei, D.; Zhong, W. Binding mechanism of coronavirus main proteinase with ligands and its implica-

- tion to drug design against SARS. *Biochem. Biophys. Res. Commun.* **2003**, *308*, 148–151.
8. Hirshberg, M.; Stockley, R. W.; Dodson, G.; Webb, M. R. The crystal structure of human rac1, a member of the rho-family complexed with a GTP analogue. *Nat. Struct. Biol.* **1997**, *4*, 147–152.
 9. Fabiola, G. F.; Krishnaswamy, S.; Nagarajan, V.; Pat-tabhi, V. C–H···O hydrogen bonds in beta sheets. *Acta Crystallogr., Sect. D.* **1997**, *53*, 316–320.
 10. Senes, A.; Ubarretxena-Belandia, I.; Engelman, D. M. The C–H···O hydrogen bond: a determinant of stability and specificity in transmembrane helix interactions. *Proc. Natl. Acad. Sci. U.S.A.* **2001**, *98*, 9056–9061.
 11. Babu, M. M.; Singh, S.; Balaram, P. A C–H···O hydrogen bond stabilized polypeptide chain reversal motif at the C terminus of helices in proteins. *J. Mol. Biol.* **2002**, *322*, 871–880.
 12. Kryger, G.; Silman, I.; Sussman, J. L. Structure of acetylcholinesterase complexed with E2020: implications for the design of new anti-alzheimer drugs. *Structure* **1999**, *7*, 297–307.
 13. Barrette-Ng, I. H.; Ng, K. K.; Mark, B. L.; Van Aken, D.; Cherney, M. M.; Garen, C.; Kolodenko, Y.; Gorbalenya, A. E.; Snijder, E. J.; James, M. N. Structure of arterivirus nsp4. The smallest chymotrypsin-like proteinase with an alpha/beta C-terminal extension and alternate conformations of the oxyanion hole. *J. Biol. Chem.* **2002**, *277*(42), 39960–39966.
 14. Bergmann, E. M.; Cherney, M. M.; Mckendrick, J.; Frommann, S.; Luo, C.; Malcolm, B. A.; Vederas, J. C.; James, M. N. Crystal structure of an inhibitor complex of the 3C proteinase from hepatitis A virus (HAV) and implications for the polyprotein processing in HAV. *Virology* **1999**, *265*(1), 153–163.
 15. Di Marco, S.; Rizzi, M.; Volpari, C.; Walsh, M. A.; Narjes, F.; Colarusso, S.; De Francesco, R.; Matassa, V. G.; Sollazzo, M. Inhibition of the hepatitis C virus NS3/4A protease. The crystal structures of two protease-inhibitor complexes. *J. Biol. Chem.* **2000**, *275*(10), 7152–7157.
 16. Mosimann, S. C.; Cherney, M. M.; Sia, S.; Plotch, S.; James, M. N. Refined X-ray crystallographic structure of the poliovirus 3C gene product. *J. Mol. Biol.* **1997**, *273*(5), 1032–1047.
 17. Murthy, H. M.; Judge, K.; DeLucas, L.; Padmanabhan, R. Crystal structure of Dengue virus NS3 protease in complex with a Bowman–Birk inhibitor: implications for flaviviral polyprotein processing and drug design. *J. Mol. Biol.* **2000**, *301*(4), 759–767.
 18. Matthews, D. A.; Dragovich, P. S.; Webber, S. E.; Fuhrman, S. A.; Patick, A. K.; Zalman, L. S.; Hendrickson, T. F.; Love, R. A.; Prins, T. J.; Marakovits, J. T.; Zhou, R.; Tikhe, J.; Ford, C. E.; Meador, J. W.; Ferre, R. A.; Brown, E. L.; Binford, S. L.; Brothers, M. A.; DeLisle, D. M.; Worland, S. T. Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes. *Proc. Natl. Acad. Sci. U.S.A.* **1999**, *96*(20), 11000–11007.
 19. Cinatl, J.; Morgenstern, B.; Chandra, P.; Rabenau, H.; Doerr, H. W. Treatment of SARS with human interferons. *The Lancet* **2003**, *362*, 293–294.